BionicM: $4.5 Million Series B First Close Brings Total Funding To $16.4 Million For Powered Prosthetics

BionicM, a Tokyo-based medical robotics company developing powered prosthetic legs, has raised ¥710 million, or approximately $4.5 million, in the first closing of its Series B financing. The investment brings the company’s cumulative equity financing and government grant funding to approximately ¥2.58 billion, equivalent to $16.4 million, and will support manufacturing expansion and U.S. commercialization ahead of the planned 2027 launch of its next-generation ASISTA prosthetic knee.

The first Series B closing includes prior investments made through J-KISS convertible equity instruments.

Participants include B Dash Ventures and Mitsubishi UFJ Capital, along with international investors and individual angel investors.

BionicM plans to use the financing to strengthen its production infrastructure, expand U.S. sales and marketing operations, and prepare for the introduction of ASISTA.

The company develops robotic prosthetic technology designed to actively assist the movements of people with lower-limb amputations.

Its products incorporate technology originating from humanoid robotics research conducted at the University of Tokyo.

Developing Powered Prosthetic Technology

BionicM was founded through research led by Xiaojun Sun during his doctoral studies at the University of Tokyo under Professor Masayuki Inaba, now Professor Emeritus.

The research focused on applying advanced robotics technology to prosthetic limbs capable of supporting human movement.

Unlike conventional prosthetic devices that primarily provide structural support or passive resistance, powered prosthetics use motors and control systems to generate movement.

These capabilities are intended to assist users during activities such as walking, standing, and navigating different surfaces.

BionicM has developed the Bio Leg, a powered prosthetic knee incorporating technology designed to support lower-limb mobility.

The company reported achieving U.S. Food and Drug Administration Class II medical device registration for Bio Leg and obtaining PDAC-verified reimbursement codes.

It has also established commercial operations in the United States.

The company’s technological and commercial progress received recognition through the 2026 Minister of Economy, Trade and Industry Award at Japan’s University-Launched Venture Awards.

These developments have helped BionicM establish a foundation for expanding its U.S. business.

ASISTA Targets The U.S. Prosthetics Market

The company’s next major product, ASISTA, is an electromechanical microprocessor knee scheduled for commercial introduction in the United States in 2027.

ASISTA incorporates a mechanism described as Flexion and Extension Assist.

Traditional microprocessor-controlled prosthetic knees commonly use hydraulic resistance to manage movement and provide stability.

BionicM’s system instead incorporates proprietary robotic actuation technology and control algorithms intended to actively assist both knee bending and straightening.

The company believes this approach can support improved mobility across different environments.

ASISTA is being designed to help users navigate grass, gravel, slopes, and uneven terrain.

Its powered assistance is also intended to reduce the physical effort required during walking.

Additional applications include supporting transitions from sitting to standing and providing controlled assistance during standing and movement.

BionicM expects the technology to address demand from prosthetic users seeking devices that do more than passively support body weight.

The company is positioning ASISTA within a U.S. market experiencing changes in both technology and reimbursement.

Reimbursement Developments Support Market Expansion

BionicM identified demographic changes and evolving reimbursement policies as important factors supporting demand for powered prosthetics.

An aging population of prosthetic users and the need for improved mobility solutions are contributing to interest in technologies that actively assist movement.

The company also highlighted the introduction of new U.S. reimbursement codes in 2025 for electromechanical control systems involving motors and actuators.

These codes distinguish powered technologies from traditional hydraulic and pneumatic mechanisms.

BionicM believes the changes can support broader adoption by providing a clearer reimbursement framework for qualifying powered prosthetic devices.

The Series B financing will allow the company to increase its manufacturing capabilities and commercial preparation as it approaches the planned ASISTA launch.

Its U.S. expansion strategy includes developing sales and marketing resources while continuing clinical and product development activities.

With $16.4 million in cumulative equity financing and government grant support, BionicM is advancing its efforts to bring humanoid robotics technology into practical prosthetic applications.

The company aims to expand access to powered mobility systems designed to reduce physical strain and improve daily movement for people who use lower-limb prostheses.

KEY QUOTES:

“Since our previous financing round, we have steadily expanded our clinical trials and commercial foundation in the United States, receiving immensely positive feedback and tangible validation from prosthetic users. We are truly encouraged to have achieved this Series B first closing with the strong support of prominent domestic and international investors.

Scheduled for U.S. release in 2027, ASISTA is a strategic product designed to transform the U.S. microprocessor knee (MPK) market through humanoid robotics innovation, introducing the nation’s first assisted electromechanical knee. Our team remains fully committed to accelerating development and business execution to realize a society where amputees can move more freely and with less fatigue.”

Xiaojun Sun, Founder And CEO Of BionicM

“In the U.S. prosthetic market, an aging demographic is driving strong demand for powered assistance, and the clinical value of powered prostheses is gaining institutional recognition, including coverage within reimbursement systems. We have reached an inflection point for widespread adoption. As one of the few companies worldwide that has successfully commercialized powered prosthetics rooted in advanced robotics from the University of Tokyo, BionicM has steadily built its commercial foothold in the U.S. We are proud to support BionicM as it pioneers the global prosthetic market with Japanese robotics innovation, scales further, and achieves lasting global success.”

Hiroyuki Watanabe, Representative Director Of B Dash Ventures

“With advancing technology, prosthetic limbs are evolving from devices that merely ‘replace lost function’ to solutions that ‘actively augment human mobility.’ BionicM is uniquely positioned to lead this transformation, combining world-class robotics engineering with a deeply user-centric approach to product development. Mitsubishi UFJ Capital is excited to support BionicM’s global growth as it takes on the world stage from Japan, expanding freedom, autonomy, and possibilities for individuals who rely on prostheses.”

Yuichi Nishio, Executive Officer And General Manager Of Investment Division III At Mitsubishi UFJ Capital